A shareholder activist group wants Hormel Foods to issue a report on "the external environmental and public health costs" of antibiotic use in the meat it sources and how those costs could affect the company, investors and the global economy.
"Hormel is aware that overuse of antibiotics puts the global health system at risk," the Shareholder Commons, a Delaware-based nonprofit, wrote in a Securities and Exchange Commission filing this week. "The company must make decisions about how much to invest in fighting AMR," or anti-microbial resistance, which can reduce the effectiveness of certain medicines in animals and humans.
The group wants shareholders to vote for the proposal at Hormel's annual meeting later this month.
The Austin, Minn.-based company's board of directors is recommending a vote against the proposal, saying such a report "would not be beneficial given the company's already robust antibiotic stewardship, continuous improvement and environmental sustainability efforts within our supply chain."
"The study requested by the stockholder proposal would incur unnecessary expense and divert management's attention from what the company is in the best position to control — ensuring stewardship of antibiotics within our supply chain," the board wrote in its proxy statement.
Hormel issued its first Antibiotic Stewardship Report in January 2021, writing that "to protect animal and human health, we must all remain vigilant stewards of antibiotics."
The Shareholder Commons says the report doesn't go far enough in addressing "the costs Hormel externalizes or the risks it creates for the global economy through the use of animals treated with antibiotics."
Hormel is among a growing list of companies seeing environmental and social issues brought to a vote at annual shareholder meetings.